These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11131956)

  • 1. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.
    Drusano GL
    J Chemother; 2000 Oct; 12 Suppl 4():21-6. PubMed ID: 11131956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.
    Drusano GL; Johnson DE; Rosen M; Standiford HC
    Antimicrob Agents Chemother; 1993 Mar; 37(3):483-90. PubMed ID: 8384815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
    Drusano GL; Preston SL; Fowler C; Corrado M; Weisinger B; Kahn J
    J Infect Dis; 2004 May; 189(9):1590-7. PubMed ID: 15116294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Corrado M
    JAMA; 1998 Jan; 279(2):125-9. PubMed ID: 9440662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
    Shapiro MA; Sesnie JC; Desaty TM; Griffin TJ; Heifetz CL
    J Antimicrob Chemother; 1998 Mar; 41(3):403-5. PubMed ID: 9578169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].
    Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of fluoroquinolones in combination with zidovudine.
    Lewin CS; Allen RA; Amyes SG
    J Med Microbiol; 1990 Oct; 33(2):127-31. PubMed ID: 2121991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose treatment of female acute uncomplicated cystitis.
    Kumamoto Y
    Infection; 1992; 20 Suppl 3():S173-4. PubMed ID: 1337061
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections.
    Teresa Tejedor M; Martín JL; Navia M; Freixes J; Vila J
    Vet Microbiol; 2003 Jul; 94(4):295-301. PubMed ID: 12829383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The importance of fluoroquinolones in treating pneumonia in the elderly].
    Belousov IuB; Efremenkova OV; Sokolov AV; Tishenkova IF
    Antibiot Khimioter; 1999; 44(12):23-6. PubMed ID: 10687030
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
    Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
    J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo selection of Pseudomonas Aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection.
    Nakano M; Yasuda M; Yokoi S; Takahashi Y; Ishihara S; Deguchi T
    Urology; 2001 Jul; 58(1):125-8. PubMed ID: 11445503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of resistance in Pseudomonas aeruginosa to fluoroquinolones.
    Speciale A; Musumeci R; Blandino G; Caccamo F; Siracusa V; Renis M
    Int J Antimicrob Agents; 2000 Mar; 14(2):151-6. PubMed ID: 10720806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone therapy in pediatrics: where we stand.
    Sabella C; Goldfarb J
    Clin Pediatr (Phila); 1997 Aug; 36(8):445-8. PubMed ID: 9272317
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of the antimicrobial activity of the fluoroquinolones.
    Maple P; Brumfitt W; Hamilton-Miller JM
    J Chemother; 1990 Oct; 2(5):280-94. PubMed ID: 2128638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.